Archive: 18/04/2016
Study drug LOXO-101 shows tumor regression in varied cancers
A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.
Apr 18, 2016